84. サルコイドーシス Sarcoidosis Clinical trials / Disease details
臨床試験数 : 149 / 薬物数 : 202 - (DrugBank : 78) / 標的遺伝子数 : 66 - 標的パスウェイ数 : 169
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05696795 (ClinicalTrials.gov) | May 1, 2023 | 13/1/2023 | Janus Kinase Inhibition in Sarcoidosis | JAK1 Inhibition in Sarcoidosis: an Opportunity for Pathogenesis Directed Therapy | Sarcoidosis | Drug: Abrocitinib 200 mg | Yale University | Pfizer | Not yet recruiting | 18 Years | N/A | All | 10 | Phase 2 | United States |
| 2 | NCT05689879 (ClinicalTrials.gov) | February 7, 2023 | 2/5/2022 | Evaluation of TNF-alpha Antagonists (Infliximab) Withdrawal in Sarcoidosis | Evaluation of TNF-alpha Antagonists (Infliximab) Withdrawal in Sarcoidosis : a Prospective, Randomized, Controlled Trial | Sarcoidosis | Drug: STOP arm | Assistance Publique - Hôpitaux de Paris | NULL | Not yet recruiting | 18 Years | N/A | All | 90 | Phase 3 | NULL |
| 3 | NCT05499637 (ClinicalTrials.gov) | November 15, 2022 | 22/6/2022 | [68Ga]Ga-PentixaFor PET/CT in Acute Myocardial Inflammation | Pilot Study to Evaluate the Accuracy of [68Ga]Ga-PentixaFor PET/CT in the Diagnosis of Three Clinical Entities of Acute Myocardial Inflammation | Acute Cellular Graft Rejection;Cardiac Sarcoidosis;Myocarditis Due to Drug | Drug: [68Ga]Ga-PentixaFor PET/CT | John O. Prior | NULL | Recruiting | 18 Years | N/A | All | 69 | Phase 2 | Switzerland |
| 4 | NCT05415137 (ClinicalTrials.gov) | September 15, 2022 | 8/6/2022 | Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis | Pulmonary Sarcoidosis | Drug: Efzofitimod 3 mg/kg;Drug: Efzofitimod 5 mg/kg;Drug: Placebo | aTyr Pharma, Inc. | Kyorin Pharmaceutical Co.,Ltd | Recruiting | 18 Years | 75 Years | All | 264 | Phase 3 | United States;Japan;Netherlands;Puerto Rico;Spain |
| 5 | EUCTR2021-004794-31-NL (EUCTR) | 01/07/2022 | 10/05/2022 | A study to Assess the Efficacy and Safety of Namilumab in subjects with lung inflammatory disease | A Randomized, Double-blind, Placebo-controlled Phase 2 Study with Open-label Extension to Assess the Efficacy and Safety of Namilumab in Subjects with Chronic Pulmonary Sarcoidosis - Resolve-Lung | chronic pulmonary sarcoidosis MedDRA version: 20.0;Level: PT;Classification code 10037430;Term: Pulmonary sarcoidosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: Namilumab Product Code: KIN-1902 INN or Proposed INN: NAMILUMAB | Kinevant Sciences GmbH | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 100 | Phase 2 | France;United States;Belgium;Turkey;Germany;Netherlands;United Kingdom | ||
| 6 | NCT05351554 (ClinicalTrials.gov) | June 30, 2022 | 4/4/2022 | A Study to Assess the Safety, Tolerability, and Efficacy of Namilumab in Participants With Active Cardiac Sarcoidosis | A Randomized, Double-blind, Placebo-controlled, Phase 2a Study With an Open-label Cohort to Assess the Safety, Tolerability, and Efficacy of Namilumab in Subjects With Active Cardiac Sarcoidosis | Sarcoidosis, Cardiac | Drug: Namilumab;Drug: Placebo;Drug: Open label Namilumab | Kinevant Sciences GmbH | NULL | Terminated | 18 Years | N/A | All | 1 | Phase 2 | United States |
| 7 | NCT05314517 (ClinicalTrials.gov) | April 30, 2022 | 30/3/2022 | A Study to Assess the Efficacy and Safety of Namilumab in Participants With Chronic Pulmonary Sarcoidosis | A Randomized, Double-blind, Placebo-Controlled Phase 2 Study With Open-label Extension to Assess the Efficacy and Safety of Namilumab in Subjects With Chronic Pulmonary Sarcoidosis | Sarcoidosis, Pulmonary | Drug: Namilumab;Drug: Placebo | Kinevant Sciences GmbH | NULL | Recruiting | 18 Years | N/A | All | 100 | Phase 2 | United States;Belgium;France;Netherlands |
| 8 | NCT05247554 (ClinicalTrials.gov) | March 1, 2022 | 9/2/2022 | Randomized Controlled Trial of Hydroxychloroquine Combined With Low-dose Corticosteroid in Pulmonary Sarcoidosis | Randomized Controlled Trial Testing the Effect of Hydroxychloroquine Combined With Low-dose Corticosteroid Therapy in Pulmonary Sarcoidosis | Pulmonary Sarcoidosis | Drug: Hydroxychloroquine + low-dose prednisone;Drug: Prednisone | Assistance Publique - Hôpitaux de Paris | NULL | Not yet recruiting | 18 Years | 80 Years | All | 200 | Phase 3 | NULL |
| 9 | NCT04924270 (ClinicalTrials.gov) | January 2022 | 7/6/2021 | Safety and Efficacy of Faecal Microbiota Transplantation in Treatment-naïve Patients With Newly Diagnosed Chronic Inflammatory Diseases | Safety and Clinical Efficacy Associated With Faecal Microbiota Transplantation Performed in Treatment-naïve Patients With Newly Diagnosed Rheumatoid Arthritis, Reactive Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Gouty Arthritis, Psoriasis, Hidradenitis Suppurativa, Pulmonary Sarcoidosis, Crohn's Disease, and Ulcerative Colitis: a 52-week, Double-blind, Randomised, Placebo-controlled, Exploratory Trial | Rheumatoid Arthritis;Reactive Arthritis;Ankylosing Spondylitis;Psoriatic Arthritis;Gouty Arthritis;Psoriasis;Hidradenitis Suppurativa;Pulmonary Sarcoidosis;Crohn Disease;Ulcerative Colitis | Biological: Faecal microbiota transplantation;Other: Placebo | Torkell Ellingsen | Region of Southern Denmark;University of Southern Denmark | Not yet recruiting | 18 Years | 70 Years | All | 200 | Phase 2 | NULL |
| 10 | JPRN-jRCTs011210048 | 05/11/2021 | 05/11/2021 | Cardiac Sarcoidosis Multi-Center Randomized Controlled Trial | Cardiac Sarcoidosis Multi-Center Randomized Controlled Trial - CHASM CS- RCT | Cardiac Sarcoidosis Cardiac Sarcoidosis | Subjects meeting the study inclusion/exclusion criteria will be randomized equally to receive either: 1. Prednisone 0.5 mg kg/day for 6-months (MAX dose 30 mg per day) or 2. Methotrexate 15-20 mg po, sc, or IM once a week for 6-months + Folic Acid 2 mg OD for 6 months + Prednisone 20 mg day for 1 month, then 10 mg OD for 1 month, then 5 mg OD for one month then STOP | Toshiyuki Nagai | NULL | Pending | >= 18age old | Not applicable | Both | 194 | Phase 3 | Canada;United States;United Kingdom;Japan |
| 11 | EUCTR2017-004219-37-DE (EUCTR) | 16/03/2021 | 29/07/2020 | Influence of Inhaled Aviptadil on Cough and Quality of life in Sarcoidosis | A randomized, prospective, multicenter, controlled and double-blinded Phase II Clinical Trial to evaluate the influence of inhaled Aviptadil on Cough and Quality of Life in Sarcoidosis patients - Avisarco II | Pulmonary sarcoidosis associated with cough MedDRA version: 20.0;Level: PT;Classification code 10037430;Term: Pulmonary sarcoidosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: Aviptadil INN or Proposed INN: Aviptadil Other descriptive name: AVIPTADIL | Universitätsklinikum Freiburg, Leitender Ärztlicher Direktor | Universitätsklinikum Freiburg, Kaufmännische Direktorin | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 200 | Phase 2 | Germany | ||
| 12 | NCT03942211 (ClinicalTrials.gov) | February 26, 2021 | 7/5/2019 | A Study in Participants With Sarcoidosis-associated Pulmonary Hypertension (SAPH) to Assess the Efficacy and Safety of Oral Selexipag | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study in Participants With Sarcoidosis-Associated Pulmonary Hypertension (SAPH) to Assess the Efficacy and Safety of Oral Selexipag. | Sarcoidosis-associated Pulmonary Hypertension | Drug: Selexipag;Drug: Placebo | Actelion | NULL | Active, not recruiting | 18 Years | 75 Years | All | 10 | Phase 2 | United States;Belgium;Brazil;Canada;France;Germany;Italy;Netherlands;Spain;United Kingdom;Czechia |
| 13 | NCT04758650 (ClinicalTrials.gov) | January 26, 2021 | 12/2/2021 | Study of 68GaNOTA-Anti-MMR-VHH2 in Oncological Lesions, Cardiovascular Atherosclerosis, Syndrome With Abnormal Immune Activation and Cardiac sarcoïdosis. | Phase II Study to Evaluate the Clinical Potential of 68GaNOTA-Anti-MMR-VHH2 for in Vivo Imaging of MMR-expressing Macrophages by Means of Positron Emission Tomography (PET) in Oncological Lesions,Cardiovascular Atherosclerosis,Syndrome With Abnormal Immune Activation and Cardiac sarcoïdosis | Squamous Cell Carcinoma of Head and Neck;Cancer;Carotid Stenosis;Atherosclerosis of Artery;Hodgkin Lymphoma, Adult;Non Hodgkin Lymphoma;HLH;Cardiac Sarcoidosis | Drug: 68GaNOTA-Anti-MMR-VHH2 | Universitair Ziekenhuis Brussel | NULL | Recruiting | 18 Years | N/A | All | 140 | Phase 2 | Belgium |
| 14 | EUCTR2018-000381-11-GB (EUCTR) | 09/11/2020 | 16/06/2020 | Study of Efficacy, Safety and Tolerability of CMK389 in Patients With Chronic Pulmonary Sarcoidosis | A subject and investigator blinded, randomized, placebo-controlled, repeat-dose, multicenter study to investigate efficacy, safety, and tolerability of CMK389 in patients with chronic pulmonary sarcoidosis | Chronic pulmonary sarcoidosis MedDRA version: 20.0;Level: PT;Classification code 10037430;Term: Pulmonary sarcoidosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Code: CMK389 INN or Proposed INN: CMK389 | Novartis Pharma AG | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 66 | Phase 2 | United States;Czech Republic;Poland;Denmark;Germany;United Kingdom | ||
| 15 | NCT04017936 (ClinicalTrials.gov) | October 23, 2020 | 9/7/2019 | Interleukin-1 Blockade for Treatment of Cardiac Sarcoidosis | Interleukin-1 Blockade for Treatment of Cardiac Sarcoidosis | Cardiac Sarcoidosis | Drug: Anakinra | Virginia Commonwealth University | American Heart Association;National Center for Advancing Translational Sciences (NCATS) | Recruiting | 21 Years | N/A | All | 28 | Phase 2 | United States |
| 16 | EUCTR2018-000381-11-PL (EUCTR) | 06/10/2020 | 23/07/2020 | Study of Efficacy, Safety and Tolerability of CMK389 in Patients With Chronic Pulmonary Sarcoidosis | A subject and investigator blinded, randomized, placebo-controlled, repeat-dose, multicenter study to investigate efficacy, safety, and tolerability of CMK389 in patients with chronic pulmonary sarcoidosis | Chronic pulmonary sarcoidosis MedDRA version: 20.0;Level: PT;Classification code 10037430;Term: Pulmonary sarcoidosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Code: CMK389 INN or Proposed INN: CMK389 | Novartis Pharma AG | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 66 | Phase 2 | United States;Czechia;Poland;Denmark;Germany;United Kingdom | ||
| 17 | ChiCTR2000036043 | 2020-10-01 | 2020-08-21 | A prospective, single-centre, diagnostic accuracy study of XpertMTB/RIF Ultra to differentiate atypical tuberculosis from sarcoidosis | A prospective, single-centre, diagnostic accuracy study of XpertMTB/RIF Ultra to differentiate atypical tuberculosis from sarcoidosis | sarcoidosis, tuberculosis | Gold Standard:Biopsy pathological specimen, and sputum AFB smear;Index test:XpertMTB/RIF Ultra; | Shanghai Pulmonary Hospital Tongji University, School of Medicine | NULL | Pending | 18 | Both | Target condition:72;Difficult condition:72 | China | ||
| 18 | NCT02523092 (ClinicalTrials.gov) | October 2020 | 10/8/2015 | Use of CXCL9 as a Biomarker of Acthar Efficacy | Use of CXCL9 as a Biomarker of Acthar Efficacy | Sarcoidosis | Drug: Acthar gel | University of California, San Francisco | Mallinckrodt | Not yet recruiting | 18 Years | 65 Years | All | 14 | Phase 4 | United States |
| 19 | NCT04064242 (ClinicalTrials.gov) | September 23, 2020 | 20/8/2019 | Study of Efficacy, Safety and Tolerability of CMK389 in Patients With Chronic Pulmonary Sarcoidosis | A Subject and Investigator Blinded, Randomized, Placebo-controlled, Repeat-dose, Multicenter Study to Investigate Efficacy, Safety, and Tolerability of CMK389 in Patients With Chronic Pulmonary Sarcoidosis | Pulmonary Sarcoidosis | Drug: CMK389;Drug: Placebo | Novartis Pharmaceuticals | NULL | Recruiting | 18 Years | 75 Years | All | 66 | Phase 2 | United States;Czechia;Denmark;Germany;Poland;United Kingdom |
| 20 | EUCTR2018-000381-11-DK (EUCTR) | 24/08/2020 | 30/06/2020 | Study of Efficacy, Safety and Tolerability of CMK389 in Patients With Chronic Pulmonary Sarcoidosis | A subject and investigator blinded, randomized, placebo-controlled, repeat-dose, multicenter study to investigate efficacy, safety, and tolerability of CMK389 in patients with chronic pulmonary sarcoidosis | Chronic pulmonary sarcoidosis MedDRA version: 20.0;Level: PT;Classification code 10037430;Term: Pulmonary sarcoidosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Code: CMK389 INN or Proposed INN: CMK389 | Novartis Pharma AG | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 66 | Phase 2 | United States;Czechia;Poland;Denmark;Germany;United Kingdom | ||
| 21 | NCT05524077 (ClinicalTrials.gov) | July 8, 2020 | 24/8/2022 | Catheter Ablation Versus Anti-arrhythmic Drugs for Ventricular Tachycardia | Catheter Ablation Versus Anti-arrhythmic Drugs for Ventricular Tachycardia (CAAD-VT): A Randomised Trial | Heart Disease Structural Disorder;Ventricular Tachycardia;Cardiomyopathy, Dilated;Sarcoidosis;Cardiomyopathy, Hypertrophic;Cardiomyopathy Ischemic;Cardiomyopathy, Familial;Arrhythmogenic Right Ventricular Cardiomyopathy 1;Arrhythmogenic Left Ventricular Cardiomyopathy | Procedure: Ablation;Drug: Anti-arrhythmic Drugs (AADs) | Western Sydney Local Health District | NULL | Recruiting | 18 Years | N/A | All | 162 | N/A | Australia |
| 22 | EUCTR2018-000381-11-DE (EUCTR) | 16/06/2020 | 31/01/2020 | Study of Efficacy, Safety and Tolerability of CMK389 in Patients With Chronic Pulmonary Sarcoidosis | A subject and investigator blinded, randomized, placebo-controlled, repeat-dose, multicenter study to investigate efficacy, safety, and tolerability of CMK389 in patients with chronic pulmonary sarcoidosis | Chronic pulmonary sarcoidosis MedDRA version: 20.0;Level: PT;Classification code 10037430;Term: Pulmonary sarcoidosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Code: CMK389 INN or Proposed INN: CMK389 | Novartis Pharma AG | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 66 | Phase 2 | United States;Czechia;Poland;Denmark;Germany;United Kingdom | ||
| 23 | NCT04314193 (ClinicalTrials.gov) | June 1, 2020 | 24/2/2020 | Effectiveness of Methotrexate Versus Prednisolone as First-line Therapy for Pulmonary Sarcoidosis | The PREDMETH Trial: Effectiveness of Methotrexate Versus Prednisolone as First-line Therapy for Pulmonary Sarcoidosis - A Randomized Controlled Trial | Sarcoidosis, Pulmonary | Drug: Methotrexate;Drug: Prednisolone | Erasmus Medical Center | St. Antonius Hospital;Longfonds | Recruiting | 18 Years | N/A | All | 138 | Phase 4 | Netherlands |
| 24 | EUCTR2018-004887-74-DE (EUCTR) | 20/05/2020 | 17/06/2019 | A study of the effectiveness and safety of selexipag in patients with sarcoidosis-associated pulmonary hypertension. | A Multicenter, Randomized, Double-blind, Placebo-controlled study in Participants With Sarcoidosis-associated Pulmonary Hypertension (SAPH) to Assess the Efficacy and Safety of Oral Selexipag. | sarcoidosis-associated pulmonary hypertension (SAPH) MedDRA version: 21.1;Level: PT;Classification code 10037400;Term: Pulmonary hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: Uptravi Product Name: Selexipag Product Code: ACT-293987 / JNJ-67896049 INN or Proposed INN: SELEXIPAG Other descriptive name: SELEXIPAG | Actelion Pharmaceuticals Ltd | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 74 | Phase 2 | United States;Czechia;Spain;Italy;United Kingdom;France;Hungary;Canada;Brazil;Belgium;Poland;Germany;Netherlands | ||
| 25 | NCT04320121 (ClinicalTrials.gov) | March 11, 2020 | 17/3/2020 | Effect of Nelutri™ on Musculoskeletal Biomarkers in Relative Sarcopenia Adults | Effect of Nelutri™ on Musculoskeletal Biomarkers in Relative Sarcopenia Adults: a Randomized, Double-blinded, Placebo-controlled Trial | Muscular Sarcoidosis | Dietary Supplement: Nelutri™;Dietary Supplement: Placebo group | Pusan National University Yangsan Hospital | NULL | Completed | 19 Months | N/A | All | 80 | N/A | Korea, Republic of |
| 26 | EUCTR2019-004148-31-NL (EUCTR) | 26/02/2020 | 15/11/2019 | The PREDMETH trial: Effectiveness of methotrexate versus prednisone as first-line therapy for pulmonary sarcoidosis – A randomized controlled trial | The PREDMETH trial: Effectiveness of methotrexate versus prednisone as first-line therapy for pulmonary sarcoidosis – A randomized controlled trial - PREDMETH trial | pulmonary sarcoidosis;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: Methotrexate Product Name: methotrexate INN or Proposed INN: methotrexate Other descriptive name: METHOTREXATE Trade Name: Prednison Product Name: Prednison INN or Proposed INN: prednisone Other descriptive name: PREDNISONE | Erasmus Medisch Centrum Dept. of Pulmonology | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 132 | Phase 4 | Netherlands | ||
| 27 | NCT03814317 (ClinicalTrials.gov) | January 30, 2020 | 4/1/2019 | Inhaled Treprostinil in Sarcoidosis Patients With Pulmonary Hypertension | An Open-Label Study of Inhaled Treprostinil in Sarcoidosis Patients With Pulmonary Hypertension and Interstitial Lung Disease (SAPPHIRE) | Sarcoidosis;Precapillary Pulmonary Hypertension;Interstitial Lung Disease | Drug: Inhaled Treprostinil | University of Florida | United Therapeutics | Recruiting | 18 Years | 99 Years | All | 10 | Phase 2 | United States |
| 28 | NCT04206163 (ClinicalTrials.gov) | January 20, 2020 | 13/12/2019 | Somatostatin Receptor Imaging in Acute Myocarditis and Cardiac Sarcoidosis | Somatostatin Receptor Imaging in Inflammatory Heart Disease | Acute Myocarditis;Cardiac Sarcoidosis | Diagnostic Test: 68Ga-DOTA-TOC PET/CT;Biological: Blood sample | Vastra Gotaland Region | NULL | Recruiting | 18 Years | 85 Years | All | 80 | N/A | Sweden |
| 29 | EUCTR2018-004244-33-DE (EUCTR) | 21/10/2019 | 15/07/2019 | A safety study with multiple doses of intravenous (in the vein) ATYR1923 in patients with pulmonary sarcoidosis | A Randomized, Double-Blind, Placebo-Controlled Multiple Ascending Dose Study of Intravenous ATYR1923 in Patients with Pulmonary Sarcoidosis | Pulmonary Sarcoidosis MedDRA version: 20.0;Level: PT;Classification code 10037430;Term: Pulmonary sarcoidosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: ATYR1923 Product Code: ATYR1923 INN or Proposed INN: Not yet available Other descriptive name: iMod.Fc, H-Fcv3-N4 | aTyr Pharma, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 36 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no | United States;Germany | ||
| 30 | NCT04109911 (ClinicalTrials.gov) | September 25, 2019 | 27/9/2019 | Effect of Fermented Oyster Extract on Musculoskeletal Biomarkers in Relative Sarcopenia Adults | Effect of Fermented Oyster Extract on Musculoskeletal Biomarkers in Relative Sarcopenia Adults: a Randomized, Double-blinded, Placebo-controlled Trial | Muscular Sarcoidosis | Dietary Supplement: Fermented oyster extract;Dietary Supplement: Placebo | Pusan National University Yangsan Hospital | NULL | Completed | 50 Years | N/A | All | 54 | N/A | Korea, Republic of |
| 31 | EUCTR2018-004887-74-IT (EUCTR) | 13/09/2019 | 17/06/2021 | A study of the effectiveness and safety of selexipag in patients with sarcoidosis-associated pulmonary hypertension. | A multicenter, randomized, double-blind, placebo-controlled study in participants with sarcoidosis-associated pulmonary hypertension (SAPH) to assess the efficacy and safety of oral selexipag. - AC-065D301 | sarcoidosis-associated pulmonary hypertension (SAPH) MedDRA version: 21.1;Level: PT;Classification code 10037400;Term: Pulmonary hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: Uptravi Product Name: Selexipag Product Code: [ACT-293987 / JNJ-67896049] INN or Proposed INN: selexipag Other descriptive name: selexipag | ACTELION PHARMACEUTICALS LTD | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 74 | Phase 2;Phase 3 | United States;Czechia;Spain;Italy;United Kingdom;France;Hungary;Canada;Brazil;Belgium;Poland;Germany;Netherlands | ||
| 32 | NCT04020380 (ClinicalTrials.gov) | September 6, 2019 | 11/7/2019 | Azithromycin a Treatment for Pulmonary Sarcoidosis | A Single Arm, Open-label Exploratory Clinical Trial of Azithromycin in Pulmonary Sarcoidosis | Sarcoidosis, Pulmonary | Drug: Azithromycin 250Mg Capsule | Hull University Teaching Hospitals NHS Trust | NULL | Completed | 18 Years | 80 Years | All | 21 | Phase 2 | United Kingdom |
| 33 | NCT04008069 (ClinicalTrials.gov) | September 3, 2019 | 25/6/2019 | Sarilumab in Patients With Glucocorticoid-Dependent Sarcoidosis | A Phase II, Single-Site, Double-Blind, Placebo-Controlled Randomized Withdrawal Study Assessing the Efficacy and Safety of Sarilumab in Patients With Glucocorticoid-Dependent Sarcoidosis | Sarcoidosis | Drug: Sarilumab 200 MG/1.14 ML Subcutaneous Solution [KEVZARA]_#1;Drug: Placebos | Stanford University | NULL | Completed | 18 Years | 80 Years | All | 15 | Phase 2 | United States |
| 34 | EUCTR2018-004887-74-HU (EUCTR) | 29/08/2019 | 25/06/2019 | A study of the effectiveness and safety of selexipag in patients with sarcoidosis-associated pulmonary hypertension. | A multicenter, randomized, double-blind, group-sequential, placebo-controlled 52-week period followed by a 104-week, single-arm, open-label period study in participants with sarcoidosis-associated pulmonary hypertension (SAPH) to assess the efficacy and safety of oral selexipag. | sarcoidosis-associated pulmonary hypertension (SAPH) MedDRA version: 20.0;Level: PT;Classification code 10037400;Term: Pulmonary hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: Uptravi Product Name: Selexipag Product Code: ACT-293987 / JNJ-67896049 INN or Proposed INN: SELEXIPAG Other descriptive name: SELEXIPAG | Actelion Pharmaceuticals Ltd | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 150 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no | Portugal;United States;Spain;Turkey;Russian Federation;Italy;United Kingdom;India;France;Hungary;Czech Republic;Mexico;Canada;Argentina;Poland;Belgium;Brazil;Romania;Denmark;Netherlands;Germany;China;Sweden | ||
| 35 | EUCTR2018-004887-74-ES (EUCTR) | 19/08/2019 | 04/07/2019 | A study of the effectiveness and safety of selexipag in patients with sarcoidosis-associated pulmonary hypertension. | A multicenter, randomized, double-blind, group-sequential, placebo-controlled 52-week period followed by a 104-week, single-arm, open-label period study in participants with sarcoidosis-associated pulmonary hypertension (SAPH) to assess the efficacy and safety of oral selexipag. | sarcoidosis-associated pulmonary hypertension (SAPH) MedDRA version: 20.0;Level: PT;Classification code 10037400;Term: Pulmonary hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: Uptravi Product Name: Selexipag Product Code: ACT-293987 / JNJ-67896049 INN or Proposed INN: SELEXIPAG Other descriptive name: SELEXIPAG | Actelion Pharmaceuticals Ltd | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 150 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no | Portugal;United States;Spain;Turkey;Russian Federation;Italy;United Kingdom;India;France;Hungary;Czech Republic;Mexico;Canada;Argentina;Poland;Belgium;Brazil;Romania;Denmark;Netherlands;Germany;China;Sweden | ||
| 36 | EUCTR2018-004887-74-GB (EUCTR) | 14/08/2019 | 03/06/2019 | A study of the effectiveness and safety of selexipag in patients with sarcoidosis-associated pulmonary hypertension. | A Multicenter, Randomized, Double-blind, Placebo-controlled Study inParticipants with Sarcoidosis-associated Pulmonary Hypertension (SAPH)to Assess the Efficacy and Safety of Oral Selexipag. | sarcoidosis-associated pulmonary hypertension (SAPH) MedDRA version: 21.1;Level: PT;Classification code 10037400;Term: Pulmonary hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: Uptravi Product Name: Selexipag Product Code: ACT-293987 / JNJ-67896049 INN or Proposed INN: SELEXIPAG Other descriptive name: SELEXIPAG | Actelion Pharmaceuticals Ltd | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 74 | Phase 2 | United States;Czechia;Spain;United Kingdom;Italy;France;Hungary;Canada;Belgium;Brazil;Poland;Germany;Netherlands | ||
| 37 | EUCTR2018-004887-74-PL (EUCTR) | 13/08/2019 | 26/06/2019 | A study of the effectiveness and safety of selexipag in patients with sarcoidosis-associated pulmonary hypertension. | A multicenter, randomized, double-blind, group-sequential, placebo-controlled 52-week period followed by a 104-week, single-arm, open-label period study in participants with sarcoidosis-associated pulmonary hypertension (SAPH) to assess the efficacy and safety of oral selexipag. | sarcoidosis-associated pulmonary hypertension (SAPH) MedDRA version: 20.0;Level: PT;Classification code 10037400;Term: Pulmonary hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: Uptravi Product Name: Selexipag Product Code: ACT-293987 / JNJ-67896049 INN or Proposed INN: SELEXIPAG Other descriptive name: SELEXIPAG | Actelion Pharmaceuticals Ltd | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 150 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no | Portugal;United States;Spain;Turkey;Russian Federation;Italy;United Kingdom;India;France;Hungary;Czech Republic;Mexico;Canada;Argentina;Poland;Belgium;Brazil;Romania;Denmark;Netherlands;Germany;China;Sweden | ||
| 38 | EUCTR2018-004887-74-NL (EUCTR) | 29/07/2019 | 05/06/2019 | A study of the effectiveness and safety of selexipag in patients with sarcoidosis-associated pulmonary hypertension. | A Multicenter, Randomized, Double-blind, Placebo-controlled Study in Participants With Sarcoidosis-associated Pulmonary Hypertension (SAPH) to Assess the Efficacy and Safety of Oral Selexipag. | sarcoidosis-associated pulmonary hypertension (SAPH) MedDRA version: 21.1;Level: PT;Classification code 10037400;Term: Pulmonary hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: Uptravi Product Name: Selexipag Product Code: ACT-293987 / JNJ-67896049 INN or Proposed INN: SELEXIPAG Other descriptive name: SELEXIPAG | Actelion Pharmaceuticals Ltd | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 74 | Phase 2 | France;United States;Hungary;Canada;Poland;Spain;Belgium;Brazil;Germany;Netherlands;United Kingdom;Italy | ||
| 39 | EUCTR2019-000580-24-GB (EUCTR) | 17/05/2019 | 25/03/2019 | A clinical trial of the antibiotic azithromycin for patients with sarcoidosis | A single arm, open-label clinical trial of azithromycin in pulmonary sarcoidosis - Azithromycin for sarcoidosis | Sarcoidosis;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: Azithromycin Product Name: Azithromycin INN or Proposed INN: azithromycin monohydrate | Hull & East Yorkshire Hospitals NHS trust | NULL | Not Recruiting | Female: yes Male: yes | 30 | Phase 2 | United Kingdom | ||
| 40 | NCT03793439 (ClinicalTrials.gov) | May 15, 2019 | 2/1/2019 | Tofacitinib Hypothesis-generating, Pilot Study for Corticosteroid-Dependent Sarcoidosis | Tofacitinib Hypothesis-generating, Pilot Study for Corticosteroid-Dependent Sarcoidosis | Sarcoidosis, Pulmonary;Sarcoidosis Lung;Sarcoidosis | Drug: Tofacitinib 5mg Oral Tablet [Xeljanz] 16 week trial;Diagnostic Test: Spirometry;Genetic: RNA Sequencing;Diagnostic Test: Laboratory testing;Drug: Corticosteroid;Drug: Tofacitinib 5mg [Xeljanz] 1 year open-label extension | Oregon Health and Science University | Pfizer | Recruiting | 18 Years | 89 Years | All | 5 | Phase 1 | United States |
| 41 | NCT03910543 (ClinicalTrials.gov) | April 11, 2019 | 4/4/2019 | Open-label Trial of Tofacitinib in Cutaneous Sarcoidosis and Granuloma Annulare | Open-label Trial of Tofacitinib in Cutaneous Sarcoidosis and Granuloma Annulare | Cutaneous Sarcoidosis;Granuloma Annulare | Drug: Tofacitinib 5 mg twice daily | Yale University | Pfizer | Completed | 18 Years | N/A | All | 15 | Phase 1 | United States |
| 42 | NCT03704610 (ClinicalTrials.gov) | March 28, 2019 | 10/10/2018 | Efficacy of Remission-induction Regimen With Infliximab for Severe Extrathoracic Sarcoidosis (EFIRTES) | Efficacy of Remission-induction Regimen With Infliximab for Severe Extrathoracic Sarcoidosis (EFIRTES STUDY) | Extrathoracic Sarcoidosis | Drug: Infliximab;Drug: Placebo | Assistance Publique - Hôpitaux de Paris | NULL | Completed | 18 Years | N/A | All | 31 | Phase 3 | France |
| 43 | EUCTR2017-004930-27-AT (EUCTR) | 05/02/2019 | 20/12/2018 | Sirolimus as treatment for patients with sarcoidosis. | Systems medicine analysis of sarcoidosis by targeting mTOR in apilot study of sirolimus as treatment in patients with sarcoidosis | Sarcoidosis with cutaneous affections;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Trade Name: Rapamune INN or Proposed INN: SIROLIMUS Other descriptive name: Rapamune Product Name: Sirolimus Ointment INN or Proposed INN: SIROLIMUS | Medical University of Vienna | NULL | Not Recruiting | Female: yes Male: yes | 20 | Phase 2 | Austria | ||
| 44 | NCT02920710 (ClinicalTrials.gov) | February 1, 2019 | 29/9/2016 | ACTHAR Therapy for Central Nervous System Sarcoidosis | ACTHAR Therapy for Central Nervous System Sarcoidosis | Sarcoidosis | Drug: Repository Corticotropin Injection | The Cleveland Clinic | Mallinckrodt | Withdrawn | N/A | N/A | All | 0 | Phase 4 | United States |
| 45 | NCT03824392 (ClinicalTrials.gov) | January 29, 2019 | 28/1/2019 | Study of Intravenous ATYR1923 for Pulmonary Sarcoidosis | A Randomized, Double-Blind, Placebo-Controlled Multiple Ascending Dose Study of Intravenous ATYR1923 in Patients With Pulmonary Sarcoidosis | Pulmonary Sarcoidosis | Biological: ATYR1923 1.0 mg/kg or placebo;Biological: ATYR1923 3.0 mg/kg or placebo;Biological: ATYR1923 5.0 mg/kg or placebo | aTyr Pharma, Inc. | Foundation for Sarcoidosis Research | Completed | 18 Years | 75 Years | All | 37 | Phase 1/Phase 2 | United States |
| 46 | NCT03593759 (ClinicalTrials.gov) | January 15, 2019 | 27/6/2018 | Cardiac Sarcoidosis Randomized Trial | Cardiac Sarcoidosis Multi-Center Randomized Controlled Trial | Cardiac Sarcoidosis;Sarcoidosis | Drug: Prednisone or Prednisolone;Drug: Methotrexate | Ottawa Heart Institute Research Corporation | Canadian Institutes of Health Research (CIHR) | Recruiting | 18 Years | N/A | All | 194 | Phase 3 | United States;Canada;Japan;United Kingdom |
| 47 | NCT03746847 (ClinicalTrials.gov) | December 1, 2018 | 29/10/2018 | PET Imaging in Patients With Suspected Cardiac Sarcoidosis | Somatostatin Receptor Imaging in Patients With Suspected Cardiac Sarcoidosis | Cardiac Sarcoidosis | Drug: Gallium-68 DOTATATE | University of Pennsylvania | Advanced Accelerator Applications | Completed | 18 Years | N/A | All | 20 | United States | |
| 48 | NCT03602976 (ClinicalTrials.gov) | August 20, 2018 | 19/7/2018 | Ursodeoxycholic Acid (UDCA) for Hepatic Sarcoidosis | A Single-center, Open Label, Cross-over Study on the Effects of Ursodeoxycholic Acid (UDCA) in Patients With Hepatic Sarcoidosis | Hepatic Sarcoidosis, Elevated Alkaline Phosphatase | Drug: Ursodeoxycholic Acid | Ethan Weinberg | American Association for the Study of Liver Diseases;Exalenz Bioscience LTD. | Completed | 18 Years | N/A | All | 6 | Phase 2 | United States |
| 49 | NCT03549598 (ClinicalTrials.gov) | July 20, 2018 | 25/5/2018 | d68Ga-DOTATATE PET/CT Assessment of Cardiac Sarcoidosis | d68Ga-DOTATATE PET/CT Assessment of Cardiac Sarcoidosis | Cardiac Sarcoidosis | Drug: 68Ga-DOTATATE PET/CT;Drug: 18FDG PET/CT scan;Drug: 13NH3 PET/CT scan | Mayo Clinic | NULL | Completed | 18 Years | N/A | All | 15 | Phase 4 | United States |
| 50 | NCT03528070 (ClinicalTrials.gov) | May 2018 | 19/4/2018 | A Clinical Study of Tranilast in the Treatment of Sarcoidosis | A Clinical Study of Tranilast in the Treatment of Sarcoidosis | Sarcoidosis | Drug: Tranilast | The First Affiliated Hospital with Nanjing Medical University | NULL | Unknown status | 18 Years | N/A | All | 56 | Early Phase 1 | NULL |
| 51 | NCT03320070 (ClinicalTrials.gov) | February 21, 2018 | 20/10/2017 | Acthar Gel in Participants With Pulmonary Sarcoidosis | A Multicenter, Randomized, Double Blind, Placebo Controlled Exploratory Study to Assess the Efficacy and Safety of Acthar Gel in Subjects With Pulmonary Sarcoidosis | Sarcoidosis, Pulmonary | Drug: Acthar Gel;Drug: Placebo | Mallinckrodt | NULL | Completed | 18 Years | 90 Years | All | 55 | Phase 4 | United States |
| 52 | NCT03705884 (ClinicalTrials.gov) | January 1, 2018 | 8/8/2018 | PET/MR Imaging In Patients With Cardiac Sarcoidosis | Molecular Imaging in Cardiovascular Disease Using Hybrid Positron Emission Tomography/Magnetic Resonance Imaging (PET/MR): Cardiac Sarcoidosis | Cardiac Sarcoidosis | Other: 18F-FDG;Drug: Prednisolone | University of Edinburgh | NULL | Unknown status | 40 Years | N/A | All | 40 | N/A | United Kingdom |
| 53 | NCT03324503 (ClinicalTrials.gov) | December 8, 2017 | 12/10/2017 | A Study to Estimate the Effect Sizes of HRCT Endpoints in Response to Glucocorticoid Induction Therapy in Subjects With Pulmonary Sarcoidosis | A Multicenter, Open-Label Study to Estimate the Effect Sizes of HRCT Endpoints in Response to GLUCOCORTICOID Induction Therapy in Subjects With Pulmonary Sarcoidosis | Sarcoidosis, Pulmonary | Drug: Glucocorticoid (prednisone or prednisolone) | Celgene | NULL | Completed | 18 Years | 65 Years | All | 8 | N/A | United States;Netherlands;United Kingdom |
| 54 | NCT03260556 (ClinicalTrials.gov) | September 27, 2017 | 22/8/2017 | Pirfenidone for Progressive Fibrotic Sarcoidosis | Pirfenidone for Progressive Fibrotic Sarcoidosis | Sarcoidosis, Pulmonary | Drug: Pirfenidone;Drug: Placebos | University of Cincinnati | Royal Brompton & Harefield NHS Foundation Trust | Recruiting | 18 Years | 90 Years | All | 60 | Phase 4 | United States |
| 55 | NCT03103490 (ClinicalTrials.gov) | August 2, 2017 | 10/3/2017 | 18F-FSPG PET/MRI or PET/CT Imaging of Cardiac Sarcoidosis or Inflammation | 18F-FSPG PET/MRI or PET/CT Imaging of Cardiac Sarcoidosis or Inflammation | Cardiac Sarcoidosis;Myocardial Inflammation | Drug: 18F-FSPG | Stanford University | GE Healthcare | Recruiting | 18 Years | N/A | All | 50 | Phase 2 | United States |
| 56 | EUCTR2016-003360-39-DE (EUCTR) | 27/06/2017 | 11/04/2017 | Safety and efficacy of Abatacept in patients with treatment-resistant sarcoidosis | Safety and efficacy of Abatacept in patients with treatment-resistant sarcoidosis - ABASARC | Steroid-refractory Sarcoidosis MedDRA version: 20.0;Level: PT;Classification code 10037430;Term: Pulmonary sarcoidosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: ORENCIA | Universitätsklinikum Freiburg | NULL | Not Recruiting | Female: yes Male: yes | 30 | Phase 2 | Germany | ||
| 57 | JPRN-UMIN000025936 | 2017/06/12 | 20/02/2017 | Japanese AntibaCterial drug maNagemEnt for cardiac Sarcoidosis Trial | Japanese AntibaCterial drug maNagemEnt for cardiac Sarcoidosis Trial - J-ACNES | Cardiac sarcoidosis | combination therapy group: Prednisolone; Predonisolone start from 30mg/day and continue same dose for one month. After one month, prednisolone decrease 25mg, 20mg, 15mg, 10mg every 2-4 weeks. Finally, maintenance dose of predonisolone is 7.5mg. Antimicrobial agent; Clarithromycin start from 400mg/day for 24weeks. Doxycycline start 100mg/day for 22 weeks after 2 months of clarithromycin therapy. Prednisolone; Predonisolone start from 30mg/day and continue same dose for one month. After one month, prednisolone decrease 25mg, 20mg, 15mg, 10mg every 2-4 weeks. Finally, maintenance dose of predonisolone is 7.5mg. | National cerebral and cardiovascular center | NULL | Complete: follow-up continuing | 20years-old | Not applicable | Male and Female | 80 | Not selected | Japan |
| 58 | NCT03402308 (ClinicalTrials.gov) | June 1, 2017 | 10/1/2018 | Effect of Schisandra Chinensis Extract on Musculoskeletal Biomakers in Relatively Sarcopenic Adults: a RCT | Effect of Schisandra Chinensis Extract on Musculoskeletal Biomakers in Relatively Sarcopenic Adults: a Randomized, Double-blinded, Placebo-controlled Trial | Muscular Sarcoidosis | Dietary Supplement: Schisandra chinensis extract;Dietary Supplement: Placebo | Pusan National University Yangsan Hospital | NULL | Completed | 50 Years | N/A | All | 54 | N/A | Korea, Republic of |
| 59 | JPRN-jRCTs031180301 | 01/05/2017 | 15/03/2019 | Antibacterial therapy for severe sarcoid uveitis | Study of antibacterial therapy for severe uveitis by sarcoidosis | Severe uveitis by sarcoidosis Other eyes and adnexal disease | Ordinary steroid medication with Clarithromycin and minomycin | Takase Hiroshi | NULL | Complete | 20age | 80age | Both | 10 | Phase 1-2 | Japan |
| 60 | NCT03265405 (ClinicalTrials.gov) | April 1, 2017 | 23/8/2017 | Efficacy and Safety of Two Glucocorticoid Regimens in the Treatment of Sarcoidosis | Efficacy and Safety of Two Glucocorticoid Regimens in the Treatment of Sarcoidosis: a Randomized Controlled Trial | Sarcoidosis | Drug: Low dose prednisolone;Drug: Medium dose prednisolone | Postgraduate Institute of Medical Education and Research | NULL | Completed | 18 Years | N/A | All | 86 | Phase 4 | India |
| 61 | NCT03259282 (ClinicalTrials.gov) | March 7, 2017 | 21/8/2017 | Gammaglobulins Level is Predictive Factor of Evolution in Sarcoidosis | Gammaglobulins Level is Predictive Factor of Evolution in Sarcoidosis | Sarcoidosis | Biological: Analysis of gamma globulin | Rennes University Hospital | NULL | Completed | N/A | N/A | All | 78 | France | |
| 62 | NCT03048097 (ClinicalTrials.gov) | February 1, 2017 | 2/2/2017 | Optimizing Acquisition Parameters and Interpretive Methods of FDG-PET/CT With Rb-82 | Optimizing Acquisition Parameters and Interpretive Methods of FDG-PET/CT With Rb-82 Myocardial Perfusion Imaging for Evaluation of Cardiac Sarcoidosis | Sarcoidosis | Drug: Fluorodeoxyglucose;Drug: Rubidium;Diagnostic Test: FDG-PET/CT with Rb82 Myocardial Perfusion Imaging | Yale University | NULL | Completed | 18 Years | N/A | All | 15 | Early Phase 1 | United States |
| 63 | NCT02888080 (ClinicalTrials.gov) | December 19, 2016 | 16/8/2016 | Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Patients With Pulmonary Sarcoidosis | A Multiple-dose, Subject and Investigator Blinded, Placebo-controlled, Parallel Design Study to Assess the Efficacy, Safety and Tolerability of ACZ885(Canakinumab) in Patients With Pulmonary Sarcoidosis | Pulmonary Sarcoidosis | Drug: ACZ885;Drug: Placebo | Novartis Pharmaceuticals | NULL | Completed | 18 Years | 80 Years | All | 40 | Phase 2 | United States;Germany;Netherlands |
| 64 | JPRN-jRCTs041180111 | 16/12/2016 | 19/03/2019 | Estimated by FDG PET/CT in Myocardial Sarcoidosis | Optimal Medical Therapy Estimated by FDG PET/CT in Myocardial Sarcoidosis - OMT-CS study | Cardiac sarcoidosis Cardiac sarcoidosis | After using PSL for 6 months, patients were classified by decreasing rate of TLG. If TLG is decreasing over 70%, PSL was prescribed 5mg/day for more 6 months. If TLG is decreasing under 70%, arm A: PSL was prescribed 30mg/day and diminishing PSL 5mg per month for more 6 months arm B: MTX (6mg/week) and folic acid (5mg/week) was prescribed for more 6 months | Murohara Toyoaki | NULL | Complete | >= 20age old | Not applicable | Both | 85 | Phase 3 | Japan |
| 65 | EUCTR2016-002160-14-NL (EUCTR) | 22/11/2016 | 25/10/2016 | Octreotide PET/CT scan for the imaging of disease activity in neurologic and cardiac sarcoidosis. | 68Ga-DOTA-NOC PET/CT for the imaging of disease activity in neurologic and cardiac sarcoidosis. - SCAN-GO Trial | Sarcoidosis.;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: Gallium-68-DOTA-N-Octreotide Product Code: Ga-68-DOTA-NOC INN or Proposed INN: Ga-68-DOTA-NOC Other descriptive name: DOTANOC | St. Antonius Hospital | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Phase 2 | Netherlands | |||
| 66 | NCT02643732 (ClinicalTrials.gov) | November 2016 | 23/12/2015 | Fatigue in Sarcoidosis - Treatment With Methylphenidate | Fatigue in Sarcoidosis - A Feasibility Study Investigating the Treatment of Fatigue in Stable Sarcoidosis Patients Using Methylphenidate | Sarcoidosis;Fatigue | Drug: Methylphenidate (overencapsulated);Drug: Placebo (Over-encapsulated tablet) | University of East Anglia | Clinical Research and Trials Unit (Norfolk & Norwich University Hospital, UK) | Recruiting | 18 Years | N/A | All | 30 | N/A | United Kingdom |
| 67 | EUCTR2016-001255-49-NL (EUCTR) | 18/10/2016 | 20/07/2016 | Study of efficacy, safety and tolerability of ACZ885 (Canakinumab) in patients with pulmonary sarcoidosis | A multiple-dose, subject- and investigator-blinded, placebo-controlled, parallel design study to assess the efficacy, safety, and tolerability of ACZ885 (canakinumab) in patients with pulmonary sarcoidosis | Pulmonary sarcoidosis MedDRA version: 20.0;Level: PT;Classification code 10037430;Term: Pulmonary sarcoidosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: ILARIS Product Code: ACZ885 INN or Proposed INN: canakinumab | Novartis Pharma Services AG | NULL | Not Recruiting | Female: yes Male: yes | 38 | Phase 2 | United States;Germany;Netherlands | ||
| 68 | JPRN-UMIN000022996 | 2016/10/08 | 04/07/2016 | Optimal Medical Therapy Estimated by FDG PET/CT in Myocardial Sarcoidosis | Optimal Medical Therapy Estimated by FDG PET/CT in Myocardial Sarcoidosis - Optimal Medical Therapy in Myocardial Sarcoidosis | Myocardial sarcoidosis | mediacl therapy with methotrexate medical therapy with steroid | The Department of Cardiology, Nagoya University Graduate School of Medicine | NULL | Recruiting | 20years-old | 90years-old | Male and Female | 50 | Not selected | Japan |
| 69 | EUCTR2016-001255-49-DE (EUCTR) | 15/08/2016 | 11/07/2016 | Study of efficacy, safety and tolerability of ACZ885 (Canakinumab) in patients with pulmonary sarcoidosis | A multiple-dose, subject- and investigator-blinded, placebo-controlled, parallel design study to assess the efficacy, safety, and tolerability of ACZ885 (canakinumab) in patients with pulmonary sarcoidosis | Pulmonary sarcoidosis MedDRA version: 20.0;Level: PT;Classification code 10037430;Term: Pulmonary sarcoidosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: ILARIS Product Code: ACZ885 INN or Proposed INN: canakinumab | Novartis Pharma Services AG | NULL | Not Recruiting | Female: yes Male: yes | 38 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no | United States;Netherlands;Germany | ||
| 70 | EUCTR2016-000342-60-GB (EUCTR) | 21/06/2016 | 06/02/2019 | Fatigue and Sarcoidosis: Treatment with Methylphenidate | Fatigue in Sarcoidosis - A feasibility study investigating the treatment of fatigue in stable sarcoidosis patients using methylphenidate - Fatigue in Sarcoidosis: Treatment with Methylphenidate | Sarcoidosis-associated fatigue (Patients with stable sarcoidosis and chronic fatigue) MedDRA version: 20.1;Level: PT;Classification code 10039486;Term: Sarcoidosis;System Organ Class: 10021428 - Immune system disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: Methylphenidate Product Name: Methylphenidate 10mg tablets Product Code: NA INN or Proposed INN: Methylphenidate Other descriptive name: None | Norfolk and Norwich University Hospital | NULL | Not Recruiting | Female: yes Male: yes | 30 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no | United Kingdom | ||
| 71 | NCT02812849 (ClinicalTrials.gov) | June 2016 | 22/6/2016 | Somatostatin Receptor Imaging in Cardiac Sarcoidosis | Somatostatin Receptor Imaging in Cardiac Sarcoidosis | Cardiac Sarcoidosis | Drug: Cu-64 DOTATATE | Rigshospitalet, Denmark | NULL | Withdrawn | 18 Years | N/A | All | 0 | Denmark | |
| 72 | NCT02298491 (ClinicalTrials.gov) | May 2016 | 14/11/2014 | CNS Sarcoidosis and Acthar Gel | Clinical Biomarkers of Disease Activity and Treatment Responses in Patients With CNS Sarcoidosis Treated With H.P. Acthar Gel | CNS Sarcoidosis | Drug: H.P. Acthar Gel | University of Maryland, Baltimore | Mallinckrodt | Completed | N/A | N/A | All | 4 | Phase 4 | United States |
| 73 | NCT02824419 (ClinicalTrials.gov) | May 2016 | 27/5/2016 | Imaging of Active Granulomas With [18F]FDG and Selected Inflammatory PET Tracers in Pulmonary Sarcoidosis | Imaging of Active Granulomas With [18F]FDG and Selected Inflammatory PET Tracers in Pulmonary Sarcoidosis | Pulmonary Sarcoidosis | Drug: Methionine;Drug: DOTANOC | Turku University Hospital | NULL | Recruiting | 18 Years | N/A | Both | 10 | Phase 2/Phase 3 | Finland |
| 74 | EUCTR2015-001815-11-FI (EUCTR) | 19/04/2016 | 29/12/2015 | PET imaging of pulmonary sarcoidosis | Imaging of active granulomas with [18F]FDG and selected inflammatory PET tracers in pulmonary sarcoidosis | Pulmonary sarcoidosis with active garnulomas in the lungs. The diagnosis is based on the clinical evidence or biopsy. MedDRA version: 18.1;Level: PT;Classification code 10037430;Term: Pulmonary sarcoidosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01] | Product Name: 18F-fluorodeoxyglucose Product Code: FDG INN or Proposed INN: FLUORINE (18F) FLUDEOXYGLUCOSE Product Name: C11-methionine INN or Proposed INN: L-methionine Other descriptive name: L-METHIONINE ([11C]METHYL) Product Name: 68Ga-DOTANOC INN or Proposed INN: DOTANOC Other descriptive name: DOTANOC | Turku PET Centre | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Finland | ||||
| 75 | NCT02546388 (ClinicalTrials.gov) | October 2015 | 9/9/2015 | Somatostatin Receptor Imaging in Patients With Suspected Cardiac Sarcoidosis | Somatostatin Receptor Imaging in Patients With Suspected Cardiac Sarcoidosis | Sarcoidosis | Drug: Indium-111 Pentreotide;Drug: Gallium-68 DOTATATE | Marcelo F. Di Carli, MD, FACC | Mallinckrodt | Completed | 18 Years | 90 Years | All | 17 | N/A | United States |
| 76 | ChiCTR-DCD-15007110 | 2015-09-01 | 2015-09-20 | The clinical application of new methods for differential diagnosis of sarcoidosis andsputum negative tuberculosis | The clinical application of new methods for differential diagnosis of sarcoidosis andsputum negative tuberculosis | sarcoidosis andsputum negative tuberculosis | Gold Standard:;Index test:; | Department of Respiratory Medicine, Shanghai Pulmonary Hospital, Tongji University School of Medicine | NULL | Recruiting | 18 | Both | Target condition:0;Difficult condition:0 | China | ||
| 77 | EUCTR2013-005333-21-NL (EUCTR) | 30/06/2015 | 08/01/2015 | Study of efficacy, safety and tolerability of ACZ885 (Canikumab) in patients with pulmonary sarcoidosis | A multiple-dose, double-blind, placebo-controlled, parallel study to assess the efficacy, safety and tolerability of ACZ885 (Canikumab) in patients with pulmonary sarcoidosis | Pulmonary sarcoidosis MedDRA version: 17.1;Level: PT;Classification code 10037430;Term: Pulmonary sarcoidosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: ILARIS Product Name: Canakinumab Product Code: ACZ885 INN or Proposed INN: Canakinumab | Novartis Pharma Services AG | NULL | Not Recruiting | Female: yes Male: yes | 90 | United States;Netherlands | |||
| 78 | EUCTR2014-002224-26-NL (EUCTR) | 07/05/2015 | 03/02/2015 | Infliximab dosing based on blood concentrations in patients with sarcoidosis: smart dosing | A new dosing strategy of infliximab versus standard dosing in patients with severe sarcoidosis: optimization of treatment - Concentration guided dosing of infliximab in sarcoidosis | Sarcoidosis;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Trade Name: Remicade Product Name: Remicade | St. Antonius Hospital | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Netherlands | ||||
| 79 | NCT02625558 (ClinicalTrials.gov) | April 2015 | 26/5/2015 | Riociguat for Sarcoidosis Associated Pulmonary Hypertension | A Double Blind, Placebo Controlled Trial of Oral Riociguat for Sarcoidosis Associated Pulmonary Hypertension | Sarcoidosis | Drug: Riociguat;Drug: Placebo | University of Cincinnati | NULL | Recruiting | 18 Years | N/A | Both | 60 | Phase 4 | United States |
| 80 | NCT02348905 (ClinicalTrials.gov) | March 2015 | 20/6/2014 | ACTHAR Gel for Cutaneous Sarcoidosis: An Open Label Trial | ACTHAR Gel for Cutaneous Sarcoidosis: An Open Label Trial | Sarcoidosis;Cutaneous Sarcoidosis | Drug: ACTHAR Gel 40 units twice weekly;Drug: ACTHAR Gel 80 units twice weekly. | Albany Medical College | NULL | Not yet recruiting | 18 Years | N/A | Both | 10 | Phase 2/Phase 3 | United States |
| 81 | NCT02155803 (ClinicalTrials.gov) | February 2015 | 30/5/2014 | ACTHAR GEL for Sarcoidosis-Associated Calcium Dysregulation: An Open-label Pilot Study | ACTHAR GEL for Sarcoidosis-Associated Calcium Dysregulation: An Open-label Pilot Study | Sarcoidosis;Hypercalcemia Due to Sarcoidosis | Drug: ACTHAR Gel (adrenocorticotropic hormone) | Albany Medical College | NULL | Not yet recruiting | 18 Years | N/A | Both | 10 | Phase 2/Phase 3 | United States |
| 82 | NCT02265874 (ClinicalTrials.gov) | January 12, 2015 | 10/10/2014 | Nicotine Treatment for Pulmonary Sarcoidosis: A Clinical Trial Pilot Study | Nicotine Treatment for Pulmonary Sarcoidosis: A Clinical Trial Pilot Study | Sarcoidosis | Drug: Habitrol;Drug: Placebo to Habitrol | Ohio State University | The Cleveland Clinic | Completed | 18 Years | 75 Years | All | 57 | Phase 1/Phase 2 | United States |
| 83 | NCT02192489 (ClinicalTrials.gov) | November 1, 2014 | 15/7/2014 | A Phase 2 Study With CC-220 in Skin Sarcoidosis | A Phase 2A, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Sequential, Dose-Ascending Study Of CC-220 In Subjects With Chronic Cutaneous Sarcoidosis | Sarcoidosis | Drug: CC-220 0.3 mg Daily;Drug: CC-220 0.6mg Daily;Drug: Placebo | Celgene | NULL | Withdrawn | 18 Years | N/A | All | 0 | Phase 2 | NULL |
| 84 | EUCTR2013-005376-17-NL (EUCTR) | 20/06/2014 | 27/02/2014 | Sandostatin therapy in sarcoidosis | Sandostatin therapy in sarcoidosis - SST in SA | Sarcoidosis MedDRA version: 16.1;Level: HLGT;Classification code 10003816;Term: Autoimmune disorders;System Organ Class: 10021428 - Immune system disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Trade Name: Sandostatin LAR INN or Proposed INN: OCTREOTIDE Other descriptive name: octreotide LAR / Sandostatin LAR (LAR=long acting release) | Erasmus Medical Center | NULL | Not Recruiting | Female: yes Male: yes | Netherlands | ||||
| 85 | NCT02188017 (ClinicalTrials.gov) | June 2014 | 24/4/2014 | Acthar Gel for Chronic Pulmonary Sarcoidosis (ACPS) | ACTHAR Gel for Chronic Pulmonary Sarcoidosis (ACPS) | Sarcoidosis;Pulmonary Sarcoidosis | Drug: Acthar gel | University of Cincinnati | Mallinckrodt | Recruiting | 18 Years | 90 Years | Both | 20 | Phase 4 | United States |
| 86 | NCT01955824 (ClinicalTrials.gov) | May 2014 | 25/9/2013 | A Trial on Clinical Efficacy of 1% Versus 2% Lignocaine in Cough Suppression and Pain Relief in Patients Undergoing Flexible Bronchoscopy | A RCT ON CLINICAL EFFICACY OF 1% vs. 2% LIGNOCAINE IN COUGH SUPPRESSION AND PAIN RELIEF IN PATIENTS UNDERGOING FLEXIBLE BRONCHOSCOPY | Lung Cancer;Tuberculosis;Sarcoidosis;Interstitial Lung Disease | Drug: 1% lignocaine;Drug: 2% lignocaine | Postgraduate Institute of Medical Education and Research | NULL | Completed | 12 Years | 80 Years | Both | 500 | Phase 2/Phase 3 | India |
| 87 | NCT02036970 (ClinicalTrials.gov) | May 2014 | 13/1/2014 | Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT | A Dose-Ranging Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension | Pulmonary Arterial Hypertension;Pulmonary Hypertension;Interstitial Lung Disease;Idiopathic Interstitial Pneumonia;Idiopathic Pulmonary Fibrosis;Sarcoidosis;Respiratory Bronchiolitis Associated Interstitial Lung Disease;Desquamative Interstitial Pneumonia;Cryptogenic Organizing Pneumonia;Acute Interstitial Pneumonitis;Idiopathic Lymphoid Interstitial Pneumonia;Idiopathic Pleuroparenchymal Fibroelastosis | Drug: Bardoxolone methyl;Drug: Placebo | Reata Pharmaceuticals, Inc. | NULL | Completed | 18 Years | 75 Years | All | 166 | Phase 2 | United States;Germany;Spain;United Kingdom |
| 88 | JPRN-UMIN000013831 | 2014/04/30 | 30/04/2014 | Effect of inhaled corticosteroid therapy in pulmonary sarcoidosis patients who manifest airflow limitation | Effect of inhaled corticosteroid therapy in pulmonary sarcoidosis patients who manifest airflow limitation - Effect of inhaled corticosteroid therapy on pulmonary sarcoidosis | Pulmonary sarcoidosis patients who revealed airflow limitation in peak flow tests, increased respiratory resistance in IOS, or increased WA% in HRCT. | inhaled ciclesonide (400maicrogram, twice daily, for three months) | Department of Respirology, Graduate School of Medicine, Chiba University, Chiba, Japan | NULL | Recruiting | 20years-old | 80years-old | Male and Female | 40 | Not selected | Japan |
| 89 | NCT01210677 (ClinicalTrials.gov) | April 2014 | 27/9/2010 | Cardiac Sarcoidosis Response To Steroids Trial | CArdiac Sarcoidosis Response TO steRoids (CASTOR) Trial | Cardiac Sarcoidosis;Sarcoidosis | Drug: Prednisone | Ottawa Heart Institute Research Corporation | NULL | Withdrawn | 18 Years | N/A | Both | 0 | Phase 4 | Canada |
| 90 | NCT02024555 (ClinicalTrials.gov) | March 2014 | 26/12/2013 | Phase II Investigation of Antimycobacterial Therapy on Progressive, Pulmonary Sarcoidosis | Investigation of the Efficacy of Antimycobacterial Therapy on Pulmonary Sarcoidosis Phase II Randomized, Double-blind, Placebo-controlled Trial | Sarcoidosis; Antimycobacterial Therapy | Drug: Levofloxacin;Drug: Ethambutol;Drug: Azithromycin;Drug: Rifampin;Drug: Placebo | Vanderbilt University | National Heart, Lung, and Blood Institute (NHLBI) | Completed | 18 Years | N/A | All | 97 | Phase 2 | United States |
| 91 | NCT02039687 (ClinicalTrials.gov) | January 2014 | 16/1/2014 | Study of Efficacy of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With Sarcoidosis | A Double Blind, Placebo Controlled Phase 2 Dose Ranging Study of the Effects of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With Sarcoidosis | Neuropathy of Sarcoidosis | Drug: ARA 290;Other: Placebo | Araim Pharmaceuticals, Inc. | NULL | Completed | 18 Years | 70 Years | All | 64 | Phase 2 | United States;Netherlands |
| 92 | NCT02134717 (ClinicalTrials.gov) | January 2014 | 30/4/2014 | Impact of Chemokine Receptor 5 (CCR5) Inhibition on Sarcoidosis Immunophenotypes | An Interventional Study of the Effect of CCR5 Inhibition With Maraviroc on Immune Cells in the the Lung and in Peripheral Blood of Patients With Sarcoidosis | Sarcoidosis | Drug: all subjects will receive maraviroc 300mg orally twice a day for 6 weeks;Procedure: Bronchoscopy with bronchoalveolar lavage;Procedure: venipunctures;Procedure: Skin biopsy | Kevin F. Gibson | University of Pittsburgh | Terminated | 18 Years | 80 Years | All | 3 | N/A | United States |
| 93 | EUCTR2013-003016-45-NL (EUCTR) | 11/09/2013 | 15/08/2013 | study the safety and effects of different doses of ARA 290 administered subcutaneously on the corneal nerve fiber density and symptoms of neuropathic pain in sarcoidosis patients. | A double blind, placebo controlled Phase 2 dose ranging study of the effects of ARA 290 on corneal nerve fiber density and neuropathic symptoms of patients with sarcoidosis - DOSARA | small fiber neuropathy;Therapeutic area: Body processes [G] - Biological Phenomena [G16] | Product Name: ARA 290 Product Code: ARA 290 INN or Proposed INN: ARA 290 | Araim Pharmaceuticals | NULL | Not Recruiting | Female: yes Male: yes | 64 | Phase 2 | United States;Netherlands | ||
| 94 | NCT01920919 (ClinicalTrials.gov) | June 2013 | 7/8/2013 | Low-dose Dexamethasone in Newly Diagnosed Pulmonary Sarcoidosis | Sarcoidosis | Drug: Dexamethasone;Drug: Placebo | St. Antonius Hospital | NULL | Recruiting | 18 Years | 60 Years | Both | 76 | Phase 3 | Netherlands | |
| 95 | EUCTR2013-000242-18-NL (EUCTR) | 23/05/2013 | 11/04/2013 | Low dose dexamethasone in newly diagnosed sarcoidosis | Low dose dexamethasone in newly diagnosed sarcoidosis - (DEXSAR) Trial | Patients with newly diagnosed, pulmonary sarcoidosis;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: Dexamethasone 0,5mg Product Name: Dexamethasone INN or Proposed INN: DEXAMETHASONE Other descriptive name: Dexamethasone | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Netherlands | |||||
| 96 | NCT01830959 (ClinicalTrials.gov) | April 2013 | 10/4/2013 | Use of Roflumilast to Prevent Exacerbations in Fibrotic Sarcoidosis Patients (REFS) | Use of Roflumilast to Prevent Exacerbations in Fibrotic Sarcoidosis Patients (REFS) | Sarcoidosis | Drug: Roflumilast;Drug: Placebo | University of Cincinnati | The Cleveland Clinic;University of Pittsburgh;University of Illinois at Chicago;Henry Ford Health System;Albany Medical College | Active, not recruiting | 18 Years | 70 Years | Both | 50 | Phase 4 | United States |
| 97 | NCT01732211 (ClinicalTrials.gov) | March 15, 2013 | 19/11/2012 | A Phase 2, Safety, Tolerability, and Efficacy Study of PD 0360324 in Chronic Pulmonary Sarcoidosis | A PHASE 2 RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, 20-WEEK SAFETY, TOLERABILITY, AND EFFICACY STUDY OF PD 0360324 IN ADULT SUBJECTS WITH CHRONIC PULMONARY SARCOIDOSIS | Pulmonary Sarcoidosis | Biological: PD 0360324;Other: Normal Saline for injection | Pfizer | NULL | Terminated | 21 Years | 75 Years | All | 1 | Phase 2 | United States |
| 98 | NCT01687517 (ClinicalTrials.gov) | October 2012 | 14/9/2012 | Efficacy and Safety of Influenza Vaccine During Sarcoidosis | Determination of the Efficacy and Safety of the Seasonal Influenza Vaccine Among Patients Suffering From Sarcoidosis. | Sarcoidosis;Influenza Vaccine | Drug: Seasonal influenza vaccine available for the 2012-2013 vaccine campaign | Assistance Publique - Hôpitaux de Paris | NULL | Completed | 18 Years | 65 Years | Both | 190 | Phase 3 | France |
| 99 | NCT01652417 (ClinicalTrials.gov) | October 2012 | 16/5/2012 | Treatment of Renal Sarcoidosis by Methylprednisolone Bolus | Randomized, Multicentric Study Evaluating the Efficacy and the Safety of Methylprednisolone Bolus in the Treatment of Renal Sarcoidosis | Renal Sarcoidosis | Drug: methylprednisolone bolus IV 15 mg/kg/d for 3 days. | Assistance Publique - Hôpitaux de Paris | NULL | Terminated | 18 Years | N/A | Both | 40 | N/A | France |
| 100 | JPRN-UMIN000008813 | 2012/01/01 | 01/09/2012 | Efficacy of antibiotic prophylaxis on postbronchoscopy fever after endobronchial ultrasound-guided transbronchial needle biopsy | Efficacy of antibiotic prophylaxis on postbronchoscopy fever after endobronchial ultrasound-guided transbronchial needle biopsy - Antibiotic prophylaxis after EBUS-TBNA | primary lung cancer, sarcoidosis, malignant lymphoma, metastatic lung tumor,mediastinal tumor, etc. | AMPC/CVA+ABPC/SBT. Control. | Respiratory medicine, Juntendo university. | NULL | Complete: follow-up complete | 20years-old | 85years-old | Male and Female | 500 | Not selected | Japan |
| 101 | ChiCTR-IOR-15005953 | 2012-01-01 | 2015-01-11 | The effects of corticosteroid treatment on asymptomatic sarcoidosis | The effects of corticosteroid treatment on asymptomatic sarcoidosis | Sarcoidosis | Corticosteroid-treated group :prednisolone ;Placebo:Placebo; | The First Affiliated Hospital, Guangzhou Medical University | NULL | Completed | 18 | 76 | Both | Corticosteroid-treated group :64;Placebo:63; | NULL | |
| 102 | EUCTR2011-003630-13-NL (EUCTR) | 22/11/2011 | 07/11/2011 | Tracer for the imaging of disease activity in sarcoidosis in the lung | 99mTc labelled anti-TNF-alpha for the imaging of disease activity in pulmonary sarcoidosis - TISS | Pulmonary sarcoidosis MedDRA version: 17.0;Level: PT;Classification code 10037430;Term: Pulmonary sarcoidosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: 99mTc-Infliximab Product Code: not applicable INN or Proposed INN: not applicable Other descriptive name: 99m technetium infliximab | Sint Antonius Hospital | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Netherlands | ||||
| 103 | NCT01587001 (ClinicalTrials.gov) | November 2011 | 10/1/2012 | The Effect of N-Acetyl-L-Cysteine, on Inflammatory and Oxidative Stress Markers in Pulmonary Sarcoidosis | The Effect of an Oral Antioxidant, N-Acetyl-L-Cysteine, on Inflammatory and Oxidative Stress Markers in Pulmonary Sarcoidosis | Pulmonary Sarcoidosis | Dietary Supplement: N-acetyl-cysteine;Drug: Placebo | National Jewish Health | American Thoracic Society | Completed | 18 Years | 80 Years | All | 17 | N/A | United States |
| 104 | NCT01440192 (ClinicalTrials.gov) | September 2011 | 19/9/2011 | Safety of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Stage II or III Pulmonary Sarcoidosis | A Phase 1B, Multi-Center, Open-Label, Single Dose Study to Evaluate the Safety of Intravenous Infusion of Human Placental-Derived Cells (PDA001) for the Treatment of Adults With Stage II or III Pulmonary Sarcoidosis.Sarcoidosis | Stage 2 Pulmonary Sarcoidosis;Stage 3 Pulmonary Sarcoidosis | Biological: PDA001 (cenplacel-L) | Celularity Incorporated | NULL | Terminated | 18 Years | 75 Years | All | 4 | Phase 1 | United States |
| 105 | NCT01324999 (ClinicalTrials.gov) | March 2011 | 24/3/2011 | Tadalafil for Sarcoidosis Associated Pulmonary Hypertension | Tadalafil for Sarcoidosis Associated Pulmonary Hypertension | Pulmonary Hypertension | Drug: Tadalafil | University of North Carolina, Chapel Hill | Eli Lilly and Company;United Therapeutics;University of Cincinnati | Completed | 18 Years | N/A | All | 12 | Phase 2/Phase 3 | United States |
| 106 | JPRN-UMIN000004267 | 2010/10/01 | 01/10/2010 | PET/CT finding of cardiac sarcoidosis | PET/CT finding of cardiac sarcoidosis - PET/CT finding of cardiac sarcoidosis | sarcoidosis | Give heparin Na before 18F-FDG PET/CT in the diagnosis of cardial sarcoidosis. | Tokushima University Hospital | NULL | Pending | Not applicable | Not applicable | Male and Female | 30 | Not selected | Japan |
| 107 | NCT03621553 (ClinicalTrials.gov) | July 1, 2010 | 17/7/2018 | Vitamin D Homeostasis in Sarcoidosis | Vitamin D Homeostasis in Sarcoidosis | Sarcoidosis;Vitamin D Insufficiency | Drug: Ergocalciferol;Drug: Placebo;Drug: Calcium Citrate with Vitamin D2 | University of Texas Southwestern Medical Center | NULL | Active, not recruiting | 21 Years | N/A | All | 90 | Phase 4 | United States |
| 108 | NCT01169038 (ClinicalTrials.gov) | July 2010 | 22/7/2010 | Investigation of the Efficacy of Antibiotics on Pulmonary Sarcoidosis | Investigation of the Efficacy of Antibiotics on Pulmonary Sarcoidosis | Pulmonary Sarcoidosis;Lung Function | Drug: levaquin; ethambutol; rifampin and azithromycin. | Vanderbilt University | NULL | Completed | 18 Years | 75 Years | All | 15 | Phase 1 | United States |
| 109 | JPRN-UMIN000006533 | 2010/04/01 | 30/10/2011 | Detecting sympathetic denervation and regional myocardial inflammation using 11C-hydroxyephedrine (HED) PET/CT and 18F-fluorodeoxyglucose (FDG) PET/CT and their relationship with arrhythmia in patients with cardiac involvement sarcoidosis and assessment of therapeutic effects | Detecting sympathetic denervation and regional myocardial inflammation using 11C-hydroxyephedrine (HED) PET/CT and 18F-fluorodeoxyglucose (FDG) PET/CT and their relationship with arrhythmia in patients with cardiac involvement sarcoidosis and assessment of therapeutic effects - Detecting sympathetic denervation and regional myocardial inflammation in patients with cardiac involvement sarcoidosis (CANVAS study) | sarcoidosis | All patients with first diagnosis of cardiac sarcoidosis or without steroid treatment will undergo 11C HED PET/CT,18F FDG PET/CT, 15O-PET water, MIBG, 12 leads ECG, AECG , SAECG and echocardiogram (Echo) before starting corticosteroid therapy and repeat study at 4 weeks after starting corticosteroid therapy. These patients will also have reevaluation 6 to 12 month after the second evaluations. Sarcoidosis without cardiac involvement will undergo steroid treatment will also repeat the same measurements 4 weeks after the treatment. Cardiac sarcoidosis but will not have steroid treatment will also repeat the same measurements 12 months later. Sarcoidosis patients without steroid treatment will also repeat the same measurements 12 months later. Cardiac sarcoidosis with steroid treatment. Cardiac sarcoidosis without steroid treatment. arcoidosis without cardiac involvement who will have steroid treatement. Sarcoidosis without cardiac involvement who will not have steroid treatement. Normal control. | Hokkaido University Graduate School of Medicine | ,NULL | Recruiting | Not applicable | Not applicable | Male and Female | 50 | Not applicable | Japan |
| 110 | NCT01074554 (ClinicalTrials.gov) | February 2010 | 8/2/2010 | Trial of Antimycobacterial Therapy in Sarcoidosis | Phase I/II Study of the Effects of Antibiotics on Sarcoidosis Pathogenesis | Sarcoidosis | Drug: Antibiotic Regimen;Drug: Placebo Regimen | Vanderbilt University | NULL | Completed | 18 Years | N/A | All | 30 | Phase 1/Phase 2 | United States |
| 111 | EUCTR2009-010714-30-IT (EUCTR) | 18/01/2010 | 11/12/2009 | A Phase 2, Multicenter, Randomized, Double blind, Parallel group, Placebo controlled Study Evaluating the Safety and Efficacy of Treatment with Ustekinumab or Golimumab in Subjects with Chronic Sarcoidosis - ND | Chronic sarcoidosis MedDRA version: 9.1;Level: LLT;Classification code 10039486 | Product Name: Ustekinumab Product Code: CNTO1275 Product Name: Golimumab Product Code: CNTO148 | CENTOCOR | NULL | Not Recruiting | Female: yes Male: yes | 180 | Phase 2 | United Kingdom;Germany;Netherlands;Denmark;Belgium;France;Italy | |||
| 112 | EUCTR2009-010714-30-NL (EUCTR) | 22/12/2009 | 03/02/2011 | A Phase 2, Multicenter, Randomized, Double blind, Parallel group, Placebo controlled Study Evaluating the Safety and Efficacy of Treatment with Ustekinumab or Golimumab in Subjects with Chronic Sarcoidosis - | Chronic sarcoidosis MedDRA version: 9.1;Level: LLT;Classification code 10039486;Term: Sarcoidosis | Product Name: Golimumab Liquid in prefilled syringe Product Code: CNTO 148 INN or Proposed INN: golimumab Other descriptive name: human anti TNF-alpha monoclonal antibody Product Name: ustekinumab liquid in prefilled syringe Product Code: CNTO1275 INN or Proposed INN: ustekinumab Other descriptive name: human anti-IL 12/23 monoclonal antibody | Centocor BV | NULL | Not Recruiting | Female: yes Male: yes | 180 | Phase 2 | United Kingdom;Germany;Netherlands;Denmark;Belgium;France;Italy | |||
| 113 | EUCTR2009-010714-30-FR (EUCTR) | 10/11/2009 | 15/10/2009 | A Phase 2, Multicenter, Randomized, Double blind, Parallel group, Placebo controlled Study Evaluating the Safety and Efficacy of Treatment with Ustekinumab or Golimumab in Subjects with Chronic Sarcoidosis | A Phase 2, Multicenter, Randomized, Double blind, Parallel group, Placebo controlled Study Evaluating the Safety and Efficacy of Treatment with Ustekinumab or Golimumab in Subjects with Chronic Sarcoidosis | Chronic sarcoidosis MedDRA version: 9.1;Level: LLT;Classification code 10039486;Term: Sarcoidosis | Product Name: Golimumab Liquid in prefilled syringe Product Code: CNTO 148 INN or Proposed INN: golimumab Other descriptive name: human anti TNF-alpha monoclonal antibody Product Name: ustekinumab liquid in prefilled syringe Product Code: CNTO1275 INN or Proposed INN: ustekinumab Other descriptive name: human anti-IL 12/23 monoclonal antibody | Centocor BV | NULL | Not Recruiting | Female: yes Male: yes | 180 | Phase 2 | France;Belgium;Denmark;Netherlands;Germany;Italy;United Kingdom | ||
| 114 | NCT00955279 (ClinicalTrials.gov) | November 2009 | 6/8/2009 | A Study to Evaluate the Safety and Effectiveness of Ustekinumab or Golimumab Administered Subcutaneously (SC) in Patients With Sarcoidosis | A Phase 2, Multicenter, Randomized, Double-Blind, Parallel-group, Placebo-controlled Study Evaluating the Safety and Efficacy of Treatment With Ustekinumab or Golimumab in Subjects With Chronic Sarcoidosis | Sarcoidosis | Drug: Placebo;Drug: Golimumab;Drug: Ustekinumab | Centocor, Inc. | NULL | Completed | 18 Years | 85 Years | All | 173 | Phase 2 | United States;Belgium;Denmark;France;Germany;Netherlands;Norway;Romania;United Kingdom;Sweden |
| 115 | EUCTR2009-010714-30-DE (EUCTR) | 23/10/2009 | 08/07/2009 | A Phase 2, Multicenter, Randomized, Double blind, Parallel group, Placebo controlled Study Evaluating the Safety and Efficacy of Treatment with Ustekinumab or Golimumab in Subjects with Chronic Sarcoidosis | A Phase 2, Multicenter, Randomized, Double blind, Parallel group, Placebo controlled Study Evaluating the Safety and Efficacy of Treatment with Ustekinumab or Golimumab in Subjects with Chronic Sarcoidosis | Chronic sarcoidosis MedDRA version: 9.1;Level: LLT;Classification code 10039486;Term: Sarcoidosis | Product Name: Golimumab Liquid in prefilled syringe Product Code: CNTO 148 INN or Proposed INN: golimumab Other descriptive name: human anti TNF-alpha monoclonal antibody Product Name: ustekinumab liquid in prefilled syringe Product Code: CNTO1275 INN or Proposed INN: ustekinumab Other descriptive name: human anti-IL 12/23 monoclonal antibody | Janssen Biologics B.V. | NULL | Not Recruiting | Female: yes Male: yes | 180 | Phase 2 | France;Belgium;Denmark;Netherlands;Germany;Italy;United Kingdom | ||
| 116 | EUCTR2009-010714-30-DK (EUCTR) | 12/10/2009 | 17/08/2009 | A Study to Evaluate the Safety and Effectiveness of Ustekinumab or Golimumab Administered Subcutaneously (SC) in Patients with Sarcoidosis | A Phase 2, Multicenter, Randomized, Double blind, Parallel group, Placebo controlled Study Evaluating the Safety and Efficacy of Treatment with Ustekinumab or Golimumab in Subjects with Chronic Sarcoidosis | Chronic sarcoidosis MedDRA version: 14.0;Level: PT;Classification code 10039486;Term: Sarcoidosis;System Organ Class: 10021428 - Immune system disorders;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15] | Product Name: Golimumab Liquid in prefilled syringe Product Code: CNTO 148 INN or Proposed INN: golimumab Other descriptive name: human anti TNF-alpha monoclonal antibody Product Name: ustekinumab liquid in prefilled syringe Product Code: CNTO1275 INN or Proposed INN: ustekinumab Other descriptive name: human anti-IL 12/23 monoclonal antibody | Janssen Biologics B.V. | NULL | Not Recruiting | Female: yes Male: yes | 180 | Phase 2 | France;United States;Belgium;Romania;Denmark;Netherlands;Germany;Italy;United Kingdom | ||
| 117 | EUCTR2009-010714-30-BE (EUCTR) | 28/09/2009 | 08/07/2009 | A Study to Evaluate the Safety and Effectiveness of Ustekinumab or Golimumab Administered Subcutaneously (SC) in Patients with Sarcoidosis | A Phase 2, Multicenter, Randomized, Double blind, Parallel group, Placebo controlled Study Evaluating the Safety and Efficacy of Treatment with Ustekinumab or Golimumab in Subjects with Chronic Sarcoidosis | Chronic sarcoidosis MedDRA version: 13.1;Level: PT;Classification code 10039486;Term: Sarcoidosis;System Organ Class: 10021428 - Immune system disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: Golimumab Liquid in prefilled syringe Product Code: CNTO 148 INN or Proposed INN: golimumab Other descriptive name: Human anti TNF-alpha monoclonal antibody Product Name: ustekinumab liquid in prefilled syringe Product Code: CNTO1275 INN or Proposed INN: ustekinumab Other descriptive name: Human anti-IL 12/23 monoclonal antibody | Janssen Biologics B.V. | NULL | Not Recruiting | Female: yes Male: yes | 180 | Phase 2 | France;United States;Belgium;Denmark;Germany;Norway;Netherlands;Italy;United Kingdom | ||
| 118 | EUCTR2009-010714-30-GB (EUCTR) | 14/09/2009 | 20/07/2009 | A Phase 2, Multicenter, Randomized, Double blind, Parallel group, Placebo controlled Study Evaluating the Safety and Efficacy of Treatment with Ustekinumab or Golimumab in Subjects with Chronic Sarcoidosis | A Phase 2, Multicenter, Randomized, Double blind, Parallel group, Placebo controlled Study Evaluating the Safety and Efficacy of Treatment with Ustekinumab or Golimumab in Subjects with Chronic Sarcoidosis | Chronic sarcoidosis MedDRA version: 9.1;Level: LLT;Classification code 10039486;Term: Sarcoidosis | Product Name: Golimumab Liquid in prefilled syringe Product Code: CNTO 148 INN or Proposed INN: golimumab Other descriptive name: human anti TNF-alpha monoclonal antibody Product Name: ustekinumab liquid in prefilled syringe Product Code: CNTO1275 INN or Proposed INN: ustekinumab Other descriptive name: human anti-IL 12/23 monoclonal antibody | Janssen Biologics B.V. | NULL | Not Recruiting | Female: yes Male: yes | 180 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no | France;Belgium;Denmark;Netherlands;Germany;Italy;United Kingdom | ||
| 119 | NCT00918554 (ClinicalTrials.gov) | September 2009 | 9/6/2009 | Efficacy Study of Methotrexate to Treat Sarcoid-associated Uveitis | Corticosteroid Sparing Effect of Methotrexate in Patients With Sarcoid- Associated Uveitis: A Double Blind, Randomized, Placebo Controlled-study -UVEXATE | Sarcoid-associated Uveitis;Ocular Sarcoidosis;Macular Edema | Drug: Methotrexate;Drug: Placebo | Assistance Publique - Hôpitaux de Paris | NULL | Terminated | 18 Years | N/A | Both | 7 | Phase 4 | France |
| 120 | NCT00855205 (ClinicalTrials.gov) | July 2009 | 3/3/2009 | Rituximab for Pulmonary Sarcoidosis | Rituximab as a Novel Therapy in Refractory Sarcoidosis: A Prospective Open- | Sarcoidosis | Drug: Rituximab | University of Cincinnati | University of Chicago | Completed | 18 Years | N/A | Both | 10 | Phase 2 | United States |
| 121 | NCT00731757 (ClinicalTrials.gov) | May 2009 | 6/8/2008 | Efficacy Study of Humira in the Treatment of Cutaneous Sarcoidosis | A Phase II, Multi-Center, Open Label Study to Determine the Efficacy of Adalimumab in the Treatment of Cutaneous Sarcoidosis | Sarcoidosis;Cutaneous Sarcoidosis | Drug: Humira | Wright State University | Stanford University | Withdrawn | 18 Years | N/A | All | 0 | Phase 2 | United States |
| 122 | NCT00926627 (ClinicalTrials.gov) | April 2009 | 22/6/2009 | Safety and Efficacy Study of Bosentan in Progressive Pulmonary Sarcoidosis | A Prospective Randomized, Double Blind, Placebo-controlled, Safety and Efficacy Study of Bosentan as add-on Therapy in Progressive Pulmonary Sarcoidosis | Sarcoidosis;Pulmonary Hypertension | Drug: bosentan;Drug: placebo | Daniel Doberer | NULL | Terminated | 18 Years | 70 Years | Both | 32 | Phase 2 | Austria |
| 123 | NCT02200146 (ClinicalTrials.gov) | March 2009 | 10/7/2014 | Hydroxychloroquine as Steroid-Sparing Agent in Pulmonary Sarcoidosis (HySSAS). | Hydroxychloroquine as Steroid-Sparing Agent in Pulmonary Sarcoidosis (HySSAS). A Multicenter, Prospective, Controlled, Randomized Trial. | Pulmonary Sarcoidosis | Drug: Prednisone;Drug: Hydroxychloroquine + Prednisone | University of Milano Bicocca | Agenzia Italiana del Farmaco | Completed | 18 Years | 70 Years | Both | 94 | Phase 3 | Italy |
| 124 | NCT01245036 (ClinicalTrials.gov) | January 2009 | 15/11/2010 | Efficacy of Antituberculous Therapy in Management of Sarcoidosis | Rifampicin and Isoniazid Along With Prednisolone Compared to Prednisolone Alone in Treatment of Sarcoidosis: a Pilot Randomized Controlled Trial | Sarcoidosis;Tuberculosis | Drug: Antituberculous therapy along with steroids | Postgraduate Institute of Medical Education and Research | NULL | Completed | 15 Years | 75 Years | Both | 100 | N/A | India |
| 125 | NCT00828828 (ClinicalTrials.gov) | December 2008 | 23/1/2009 | Antibody Response to Influenza Vaccine in Patients With Sarcoidosis | Controlled Trial of Serologic Efficacy of Influenza Vaccine in Patients With Sarcoidosis | Pulmonary Sarcoidosis | Biological: Influenza Vaccine | Shahid Beheshti Medical University | NULL | Completed | 20 Years | 60 Years | Both | 49 | Iran, Islamic Republic of | |
| 126 | NCT00794274 (ClinicalTrials.gov) | November 2008 | 19/11/2008 | The Efficacy and Safety of CC-10004 in Chronic Cutaneous Sarcoidosis | The Efficacy and Safety of CC-10004 in Chronic Cutaneous Sarcoidosis | Sarcoidosis;Cutaneous Sarcoidosis | Drug: CC-100004 | University of Cincinnati | Celgene Corporation;Medical University of South Carolina | Completed | 18 Years | 80 Years | Both | 15 | Phase 2/Phase 3 | United States |
| 127 | NCT00851929 (ClinicalTrials.gov) | November 2008 | 24/2/2009 | Ambrisentan (Letairis) for Sarcoidosis Associated Pulmonary Hypertension | Ambrisentan (Letairis) for Sarcoidosis Associated Pulmonary Hypertension | Sarcoidosis;Pulmonary Hypertension | Drug: Ambrisentan | Medical University of South Carolina | Gilead Sciences | Completed | 18 Years | 99 Years | All | 16 | Phase 2/Phase 3 | United States |
| 128 | NCT00739960 (ClinicalTrials.gov) | August 2008 | 20/8/2008 | Safety Study of Abatacept to Treat Refractory Sarcoidosis | Sarcoidosis, Trial of Abatacept in Refractory Disease (STAR). A Prospective Open-Label Trial of Abatacept in Progressive Sarcoidosis | Sarcoidosis | Drug: Abatacept | University of Chicago | Bristol-Myers Squibb | Terminated | 18 Years | N/A | All | 1 | Phase 2 | United States |
| 129 | NCT00701207 (ClinicalTrials.gov) | July 2008 | 17/6/2008 | Study of Nicotine Patches in Patients With Sarcoidosis | Modulation of Pulmonary Sarcoidosis by Nicotinic Acetylcholine Receptors | Pulmonary Sarcoidosis | Drug: nicotine patch | Elliott Crouser MD | American Thoracic Society | Completed | 18 Years | N/A | All | 64 | Early Phase 1 | United States |
| 130 | EUCTR2008-001340-39-IT (EUCTR) | 30/06/2008 | 13/06/2008 | Hydroxychloroquine as Steroid-Sparing Agent in pulmonary Sarcoidosis (HySSAS). A multicenter, prospectic, controlled, randomized trial. - HySSAS | Hydroxychloroquine as Steroid-Sparing Agent in pulmonary Sarcoidosis (HySSAS). A multicenter, prospectic, controlled, randomized trial. - HySSAS | Pulmonary Sarcoidosis | Trade Name: PLAQUENIL*25CPR RIV 200MG INN or Proposed INN: Hydroxychloroquine Trade Name: DELTACORTENE*10CPR 25MG INN or Proposed INN: Prednisone | UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Italy | ||||
| 131 | EUCTR2007-005117-18-AT (EUCTR) | 03/04/2008 | 04/03/2008 | Safety and efficacy study of bosentan in progressive pulmonary sarcoidosis - BOPSAC | Safety and efficacy study of bosentan in progressive pulmonary sarcoidosis - BOPSAC | Progressive pulmonary sarcoidosis MedDRA version: 9.1;Level: PT;Classification code 10037430;Term: Pulmonary sarcoidosis | Trade Name: Tracleer Product Name: Bosentan | Medical University of Vienna, Department of Clinical Pharmacology | NULL | Not Recruiting | Female: yes Male: yes | Austria | ||||
| 132 | NCT00581607 (ClinicalTrials.gov) | April 2008 | 26/12/2007 | Double Blind, Randomized Trial of Bosentan for Sarcoidosis Associated Pulmonary Hypertension | Double Blind, Randomized Trial of Bosentan for Sarcoidosis Associated Pulmonary Hypertension | Sarcoidosis;Pulmonary Arterial Hypertension | Drug: Bosentan;Drug: Placebo | University of Cincinnati | Actelion | Completed | 18 Years | N/A | Both | 43 | Phase 2/Phase 3 | United States |
| 133 | NCT02829853 (ClinicalTrials.gov) | January 2008 | 4/7/2016 | Clinical and Genetic Study of Familial Sarcoidosis (SARCFAM) | Clinical and Genetic Study of Familial Sarcoidosis (SARCFAM) | Sarcoidosis | Genetic: Genetic analysis by SANGER and WHOLE EXOME NEXT GENERATION SEQUENCING | Hospices Civils de Lyon | NULL | Recruiting | 8 Years | 80 Years | Both | 800 | N/A | France |
| 134 | NCT00555347 (ClinicalTrials.gov) | October 2007 | 7/11/2007 | Use of Armodafinil for Fatigue in Sarcoidosis | Use of Armodafinil (R-modafinil) for Fatigue in Sarcoidosis | Sarcoidosis;Fatigue;Sleepiness | Drug: Armodafinil;Drug: Placebo | University of Cincinnati | Cephalon | Completed | 18 Years | N/A | Both | 20 | Phase 2/Phase 3 | United States |
| 135 | NCT00690911 (ClinicalTrials.gov) | August 2007 | 2/6/2008 | Study to Determine the Efficacy of Adalimumab in the Treatment of Cutaneous Sarcoidosis | A Phase II, Multi-Center, Open Label Study to Determine the Efficacy of Adalimumab in the Treatment of Cutaneous Sarcoidosis (HUM 04-36) | Sarcoidosis | Drug: adalimumab | Wake Forest University | NULL | Withdrawn | 18 Years | N/A | All | 0 | Phase 2 | United States |
| 136 | EUCTR2006-005361-19-GB (EUCTR) | 09/03/2007 | 17/12/2006 | Evaluation of the efficacy of the dual endothelin 1 receptor antagonist Bosentan in the treatment of Pulmonary Hypertension secondary to Chronic Obstructive Pulmonary Disease and in the treatment of Pulmonary Hypertension secondary to sarcoidosis | Evaluation of the efficacy of the dual endothelin 1 receptor antagonist Bosentan in the treatment of Pulmonary Hypertension secondary to Chronic Obstructive Pulmonary Disease and in the treatment of Pulmonary Hypertension secondary to sarcoidosis | Pulmonary Hypertension secondary to Chronic Obstructive Pulmonary Disease and secondary to Sarcoid Patients devolop pulmonary hypertension for various reasons, two common causes are Chronic Obstructive Pulmonary disease and Sarcoid. Once developed it may go on to cause right heart failure and severe breathlessness and eventually death. We believe that the use of bosentan may lower the pulmonary hypertension and improve symptoms. MedDRA version: 8.1;Level: LLT;Classification code 10037400;Term: Pulmonary hypertension | Trade Name: Tracleer Product Name: tracleer INN or Proposed INN: Bosentan monohydrate | St Georges Hospital | NULL | Not Recruiting | Female: yes Male: yes | 45 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yes | United Kingdom | ||
| 137 | NCT00403650 (ClinicalTrials.gov) | November 2006 | 24/11/2006 | Inhaled Iloprost for Sarcoidosis-associated Pulmonary Hypertension | Inhaled Iloprost for Sarcoidosis Associated Pulmonary Hypertension | Sarcoidosis;Pulmonary Arterial Hypertension | Drug: Iloprost | University of Cincinnati | NULL | Completed | 18 Years | 90 Years | Both | 20 | Phase 4 | United States |
| 138 | NCT00274352 (ClinicalTrials.gov) | September 2006 | 6/1/2006 | A Study of Adalimumab to Treat Sarcoidosis of the Skin | A Double-Blind, Randomized, Placebo-Controlled Study of Adalimumab in the Treatment of Cutaneous Sarcoidosis | Sarcoidosis | Drug: adalimumab | Pariser, Robert J., M.D. | Abbott;Virginia Clinical Research, Inc. | Completed | 18 Years | 89 Years | Both | 16 | Phase 2 | United States |
| 139 | NCT00361387 (ClinicalTrials.gov) | June 2006 | 7/8/2006 | Use of Focalin for Fatigue in Sarcoidosis | Randomized, Double-Blind, Placebo-Controlled Study of Dexmethylphenidate Hydrochloride, (d-MPH) in the Treatment of Fatigue in Sarcoidosis Subjects. | Sarcoidosis | Drug: d-methylphenidate | University of Cincinnati | NULL | Completed | 18 Years | N/A | Both | 12 | Phase 4 | United States |
| 140 | EUCTR2006-001816-56-DK (EUCTR) | 11/05/2006 | 28/04/2006 | Can PET scan be used to assess disease activity in patients with sarcoidosis during treatment with adalimumab (Humira)? - KOMPLET | Can PET scan be used to assess disease activity in patients with sarcoidosis during treatment with adalimumab (Humira)? - KOMPLET | sarcoidosis | Trade Name: Humira Product Name: Humira | Rigshospitalet | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 10 | Phase 2 | Denmark | ||
| 141 | NCT00311246 (ClinicalTrials.gov) | April 2006 | 3/4/2006 | Trial of Adalimumab in Progressive Sarcoidosis | A Prospective Open-Label Trial of Adalimumab in Progressive Sarcoidosis | Sarcoidosis | Drug: Adalimumab | University of Chicago | Abbott | Terminated | 18 Years | 85 Years | All | 11 | Phase 2 | United States |
| 142 | NCT00402623 (ClinicalTrials.gov) | January 2006 | 20/11/2006 | The Effect of Quercetin in Sarcoidosis | The Effect of Quercetin on the Increased Inflammatory and Decreased Antioxidant Status in Sarcoidosis | Sarcoidosis | Dietary Supplement: quercetin;Other: placebo | Maastricht University Medical Center | ZonMw: The Netherlands Organisation for Health Research and Development | Completed | N/A | N/A | All | 18 | N/A | Netherlands |
| 143 | NCT00279708 (ClinicalTrials.gov) | January 2006 | 18/1/2006 | Atorvastatin to Treat Pulmonary Sarcoidosis | Atorvastatin as a Disease Modifying Agent in Stage II and III Pulmonary Sarcoidosis: A Randomized, Double-Blind, Placebo-Controlled Trial | Sarcoidosis, Pulmonary | Drug: Atorvastatin;Other: Placebo Oral Tablet | National Heart, Lung, and Blood Institute (NHLBI) | NULL | Completed | 18 Years | 70 Years | All | 55 | Phase 2 | United States |
| 144 | NCT00305552 (ClinicalTrials.gov) | February 2005 | 21/3/2006 | SARCOTHAL. Thalidomide in Skin Sarcoidosis | Randomized Controlled Trial of Thalidomide vs Placebo in Skin Sarcoidosis | Sarcoidosis | Drug: THALIDOMIDE | Assistance Publique - Hôpitaux de Paris | NULL | Completed | 18 Years | N/A | Both | 40 | Phase 3 | France |
| 145 | NCT00282438 (ClinicalTrials.gov) | December 2003 | 24/1/2006 | Hematopoietic Stem Cell Support in Patients With Refractory Sarcoidosis | Hematopoietic Stem Cell Transplant in Patients With Refractory Sarcoidosis: A Phase I/II Trial | Sarcoidosis | Biological: Autologous hematopoietic stem cell transplantation;Biological: Allogeneic stem cell transplantation | Northwestern University | NULL | Terminated | 18 Years | 60 Years | All | 2 | Phase 1/Phase 2 | United States |
| 146 | NCT00073437 (ClinicalTrials.gov) | October 2003 | 20/11/2003 | A Study of Infliximab in Patients With Sarcoidosis | A Multicenter, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Safety and Efficacy of Infliximab (Remicade?) in Subjects With Chronic Sarcoidosis With Pulmonary Involvement. | Sarcoidosis | Drug: Infliximab | Centocor, Inc. | NULL | Completed | 18 Years | N/A | Both | 139 | Phase 3 | United States;Austria;Belgium;France;Germany;Netherlands;Sweden;Switzerland;United Kingdom;Italy |
| 147 | NCT00262132 (ClinicalTrials.gov) | September 2003 | 5/12/2005 | Mycophenolate for Pulmonary Sarcoidosis | Mycophenolate for Pulmonary Sarcoidosis | Pulmonary Sarcoidosis | Drug: Mycophenolate | Medical University of South Carolina | Hoffmann-La Roche | Terminated | 18 Years | N/A | All | 20 | Phase 3 | United States |
| 148 | NCT00001877 (ClinicalTrials.gov) | February 1999 | 3/11/1999 | Treatment of Pulmonary Sarcoidosis With Pentoxifylline | Treatment of Pulmonary Sarcoidosis With Pentoxifylline | Pulmonary Sarcoidosis | Drug: Pentoxifylline | National Heart, Lung, and Blood Institute (NHLBI) | NULL | Completed | N/A | N/A | Both | 100 | Phase 2 | United States |
| 149 | NCT00000596 (ClinicalTrials.gov) | June 1978 | 27/10/1999 | Diffuse Fibrotic Lung Disease | Lung Diseases;Pulmonary Fibrosis;Sarcoidosis | Drug: prednisone;Drug: cyclophosphamide;Drug: dapsone | National Heart, Lung, and Blood Institute (NHLBI) | NULL | Completed | 18 Years | N/A | Both | Phase 2 | NULL |